PMID- 30992255
OWN - NLM
STAT- MEDLINE
DCOM- 20190813
LR  - 20190813
IS  - 0253-9772 (Print)
IS  - 0253-9772 (Linking)
VI  - 41
IP  - 4
DP  - 2019 Apr 20
TI  - [The third-generation sequencing combined with targeted capture technology for 
      high-resolution HLA typing and MHC region haplotype identification].
PG  - 337-348
LID - 10.16288/j.yczz.18-282 [doi]
AB  - The high-resolution and accurate typing of human leukocyte antigen (HLA) is of 
      great significance for the study of tissue matching in organ transplantation and 
      the correlation between HLA and disease. In this study, the peripheral blood of 
      12 patients with primary hepatocellular carcinoma was used to compare the 
      advantages and disadvantages of the next- and third-generation sequencing 
      technology for high-resolution HLA typing. In addition, probe capture technology 
      was used to capture the MHC region of YH and HeLa standard cell lines, and a 
      primary hepatocellular carcinoma patient. The captured products were sequenced 
      using PacBio platform to assess the potential of ultra-long reads sequencing 
      technology for analysis of the entire MHC region. Our results showed that: (1) 
      the next- and third-generation sequencing technology can both achieve 6-8 digit 
      high resolution in HLA typing. However, the coverage of the third-generation is 
      significantly better than the next-generation sequencing technology. (2) The 
      ultra-long reads of the third generation sequencing can directly span the entire 
      amplicon region, which has obvious advantages for haplotype phasing, with 92.79% 
      of the HLA genes having accurate phasing results, which is much higher than the 
      75.65% from the next-generation data. (3) The long-reads from the third 
      generating sequencing can not only be used to assemble the MHC region but also 
      the ability to phase the entire MHC region of 3.6 Mb, thereby helping to clarify 
      the localization information of the mutation sites, alleles and non-coding 
      regions on each MHC haplotype, and providing a theoretical basis for the study of 
      immune and other related diseases.
FAU - Chen, Jia
AU  - Chen J
AD  - Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of 
      Education, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, 
      China.
FAU - Shu, Ming Yue
AU  - Shu MY
AD  - Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of 
      Education, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, 
      China.
FAU - Li, Jin
AU  - Li J
AD  - Deparement of Laboratory,Zhongnan Hospital of Wuhan University, Wuhan 430071, 
      China.
FAU - Fu, Ai Si
AU  - Fu AS
AD  - Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of 
      Education, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, 
      China.
FAU - Yang, Fan
AU  - Yang F
AD  - Public Technology Service Platform, Wuhan Institute of Biotechnology, Wuhan 
      430071, China.
FAU - Wang, Zou
AU  - Wang Z
AD  - Public Technology Service Platform, Wuhan Institute of Biotechnology, Wuhan 
      430071, China.
FAU - Li, Yi Rong
AU  - Li YR
AD  - Deparement of Laboratory,Zhongnan Hospital of Wuhan University, Wuhan 430071, 
      China.
FAU - Deng, Zi Xin
AU  - Deng ZX
AD  - Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of 
      Education, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, 
      China.
FAU - Liu, Tian Gang
AU  - Liu TG
AD  - Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of 
      Education, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, 
      China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Yi Chuan
JT  - Yi chuan = Hereditas
JID - 9436478
RN  - 0 (HLA Antigens)
MH  - Alleles
MH  - Carcinoma, Hepatocellular/genetics
MH  - HLA Antigens/*genetics
MH  - *Haplotypes
MH  - HeLa Cells
MH  - *High-Throughput Nucleotide Sequencing
MH  - *Histocompatibility Testing
MH  - Humans
MH  - Liver Neoplasms/genetics
MH  - Sequence Analysis, DNA
EDAT- 2019/04/18 06:00
MHDA- 2019/08/14 06:00
CRDT- 2019/04/18 06:00
PHST- 2019/04/18 06:00 [entrez]
PHST- 2019/04/18 06:00 [pubmed]
PHST- 2019/08/14 06:00 [medline]
AID - 10.16288/j.yczz.18-282 [doi]
PST - ppublish
SO  - Yi Chuan. 2019 Apr 20;41(4):337-348. doi: 10.16288/j.yczz.18-282.